Emerging drugs for endometrial cancer

Bibliography

• Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Antoine J, Bray FI, et al. Trends in corpus uteri cancer mortality in member states of the European Union. Eur J Cancer 2014;50:1675-84
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17
   PubMed Web of Science ®Google Scholar
• Singh P, Smith CL, Cheetham G, et al. Serous carcinoma of the uterus – determination ofHER- 2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. Int J Gynecol Cancer 2008;18:1344-51
   PubMed Web of Science ®Google Scholar
• Alvarez T, Miller E, Duska L, et al. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type i or type ii endometrial carcinoma? Am J Surg Pathol 2012;36:753-61
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Wang D, Kesterson J, et al. Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma. PLoS One 2011;6:e18066
   PubMedGoogle Scholar
• Moore KN, Fader NA. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011;54:278-91
   PubMed Web of Science ®Google Scholar
• Schwartz PE. The management of serous papillary uterine cancer. Curr Opin Oncol 2006;18(5):494-9
   PubMed Web of Science ®Google Scholar
• Goff BA. Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol Oncol 2005;98(3):341-3
   PubMed Web of Science ®Google Scholar
• Zagouri F, Bozas G, Kafantari E, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int 2010;2010:749579
   PubMedGoogle Scholar
• National Cancer Institute. Surveillance epidemiology and end results. SEER stat fact sheets; corpus and uterus, NOS. Available from: http://seer.cancer.gov/statfacts/html/corp.html
   Google Scholar
• Dowdy SC, Borah BJ, Bakkum-Gamez JN, et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol 2012;127:5-10
   PubMed Web of Science ®Google Scholar
• Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2011;22:35-9
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology: uterine neoplasms. Version 1. 2013
   Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012;125:abstract 771
   Web of Science ®Google Scholar
• Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007;25:2983-90
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007;33:177-90
   PubMed Web of Science ®Google Scholar
• Dellinger TH, Monk BJ. Systemic therapy for recurrent endometrial cancer: a review of North American trials. Expert Rev Anticancer Ther 2009;9:905-16
   PubMed Web of Science ®Google Scholar
• Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 2013;131:567-73
   PubMed Web of Science ®Google Scholar
• Wartko P, Sherman ME, Hannah P, et al. Recent changes in endometrial cancer trends among menopausal-age US women. Cancer Epidemiol 2013;37:374-7
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the US: 2010 – 2020. J Natl Cancer Inst 2011;103:117-28
   PubMed Web of Science ®Google Scholar
• de Oliveira C, Bremner K.E, Pataky R, et al. Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open 2013;1(1):E1-8
   Google Scholar
• Morice P, Levy-Piedbois C, Ajaj S, et al. Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. Eur J Cancer 2001;37:985-90
   PubMed Web of Science ®Google Scholar
• Agboola OO, Grunfeld E, Coyle D, et al. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. Can Med Assoc J 1997;157:879-88
   PubMed Web of Science ®Google Scholar
• Tjalma WA, Van Dam PA, et al. The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer 2004;14:931-7
   PubMed Web of Science ®Google Scholar
• Kharma B, Baba T, Mandai M, et al. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. Int J Cancer 2013;133:2234-44
   PubMed Web of Science ®Google Scholar
• Sherman ME, Bur ME, Kurman RJ. p53in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1288-74
   Google Scholar
• Sherman ME. Theories of endometrial carcinogenesis : a multidisciplinary approach. Mod Pathol 2000;13(3):295-308
   PubMed Web of Science ®Google Scholar
• Risinger JI, Hayas AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57(21):4736-8
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng B-J, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of theAkt/PKB survival pathway. Oncogene 2008;27:1749-58
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18:5856-64
   PubMed Web of Science ®Google Scholar
• Acharya S, Hensley ML, Montag AC, et al. Rare uterine cancers. Lancet Oncol 2005;6:961-71
   PubMed Web of Science ®Google Scholar
• Niikura H, Sasano H, Matsunaga G, et al. Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum Pathol 1995;26:892-6
   PubMed Web of Science ®Google Scholar
• Konecny GE, Santos L, Winterhoff B, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 2009;100:89-95
   PubMed Web of Science ®Google Scholar
• Holland CM, Day K, Evans A, et al. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 2003;89:891-8
   PubMed Web of Science ®Google Scholar
• Zhang J, Ma L. MicroRNA control of epithelialmesenchymal transition and metastasis. Cancer Metastasis Rev 2012;31:3653-462
   Google Scholar
• Hubbard SA, Friel AM, Kumar B, et al. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res 2009;69:8241-8
   PubMed Web of Science ®Google Scholar
• Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001;91:22-6
   PubMed Web of Science ®Google Scholar
• Moreno-Bueno G, Hardisson D, S´anchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-90
   PubMed Web of Science ®Google Scholar
• Liao X, Siu MK, Chan KY, et al. Hypermethylation of RAS effector related genes andDNAmethyltransferase 1 expression in endometrial carcinogenesis. Int J Cancer 2008;123:296-302
   PubMed Web of Science ®Google Scholar
• Yi TZ, Guo J, Zhou L, et al. Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. Cancer Invest 2011;29:86-92
   PubMed Web of Science ®Google Scholar
• Basil JB, Goodfellow PJ, Rader JS, et al. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000;89(8):1758-64
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
   PubMed Web of Science ®Google Scholar
• Varughese J, Cocco E, Bellone S, et al. Uterine serous papillary carcinomas overexpress human trophoblast-cell- surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Cancer 2011;117:3163-72
   PubMed Web of Science ®Google Scholar
• El-Sahwi K, Bellone S, Cocco E, et al. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther 2010;9:57-66
   PubMed Web of Science ®Google Scholar
• Kiefel H, Bondong S, Hazin J, et al. L1CAM: a major driver for tumor cell invasion andmotility. Cell Adh Migr 2012;6:374-84
   PubMed Web of Science ®Google Scholar
• Bosse T, Nout RA, Stelloo E, et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer 2014; In press
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73
   PubMed Web of Science ®Google Scholar
• Widakowich C, de Castro G Jr, Azambuja E, et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12:1443-55
   PubMed Web of Science ®Google Scholar
• Morgillo F, Bareschino MA, Bianco R, et al. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007;75:788-99
   PubMed Web of Science ®Google Scholar
• Glasspool RM, Teodoridis JM, Brown R. Epigenetics as amechanism driving polygenic clinical drug resistance. Br J Cancer 2006;94:1087-92
   PubMed Web of Science ®Google Scholar
• Ogawa T, Liggett TE, Melnikov AA, et al. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle 2012;11:1656-63
   PubMed Web of Science ®Google Scholar
• Ghosh G, Lian X, Kron SJ, et al. Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors. BMC Cancer 2012;12:95
   PubMedGoogle Scholar
• Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63:201-12
   PubMed Web of Science ®Google Scholar
• Pivot X, Villanueva C, Chaigneau L, et al. Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs 2008;17:593-9
   PubMed Web of Science ®Google Scholar
• Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-p. J Clin Oncol 2009;27:3104-8
   PubMed Web of Science ®Google Scholar
• Nagy A, Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005;73:851-9
   PubMed Web of Science ®Google Scholar
• Völker P, Grundker C, Schmidt O, et al. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct anti-proliferative activity of luteinizing-hormone releasing hormone analogs. Am J Obstet Gynecol 2002;186:171-9
   PubMed Web of Science ®Google Scholar
• Westphalen S, Kotulla G, Kaiser F, et al. Receptor-mediated antiproliferative effects of the cytotoxic LHRHagonistAN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000;17:1063-9
   PubMed Web of Science ®Google Scholar
• Emons G, Ortmann O, Schulz KD, et al. Growth-inhibitory actions of analogues of luteinizing hormoneYreleasing hormone on tumor cells. Trends Endocrinol Metab 1997;8:355-62
   PubMed Web of Science ®Google Scholar
• Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Contr 2009;16:38-45
   PubMed Web of Science ®Google Scholar
• Bajo AM, Schally AV, Halmos G, et al. Targeted doxorubicin-containing luteinizing hormoneYreleasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 2003;9:3742-8
   PubMed Web of Science ®Google Scholar
• Emons G, Sindermann H, Engel J, et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 2009;90:15Y18
   Google Scholar
• Grundker C, Volker P, Griesinger F, et al. Antitumor effects of the cytotoxic luteinizing hormoneYreleasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002;187:528-37
   PubMed Web of Science ®Google Scholar
• Emons G, Gorchev G, Harter P, et al. Efficacy and Safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). Int J Gynecol Cancer 2014;24:260-5
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;29:2259-65
   PubMed Web of Science ®Google Scholar
• Wright JD, Powell MA, Rader JS, et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007;27:3525-8
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012;127:538-43
   PubMed Web of Science ®Google Scholar
• Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer. A promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 2014;138:343-50
   PubMed Web of Science ®Google Scholar
• Albitar L, Carter MB, Davies S, et al. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer. Gynecol Oncol 2007;106:94-104
   PubMed Web of Science ®Google Scholar
• Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:15-20
   PubMed Web of Science ®Google Scholar
• Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129:486-94
   PubMed Web of Science ®Google Scholar
• Konecny GE, Venkatesan N, Yang G, et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer 2008;98:1076-84
   PubMed Web of Science ®Google Scholar
• KiLeslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127:345-50
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group. J Clin Oncol 2011;29:3278-85
   PubMed Web of Science ®Google Scholar
• Goodwin RA, Jamal R, Tuc D, et al. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 2013;13:315-20
   Google Scholar
• Ray-Coquard I, Favier L, Weber B, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 2013;108:1771-7
   PubMed Web of Science ®Google Scholar
• . Acevedo-Gadea C, Santin AD, Higgins SA, et al.Phase I. Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer. Int J Gynecol Cancer 2014;24:528-33
   PubMed Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2014;132:585-92
   PubMed Web of Science ®Google Scholar
• Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 2013;108:1021-6
   PubMed Web of Science ®Google Scholar
• Bradford LS, Rauh-Hain A, Clarka RM, et al. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecol Oncol 2014;133:346-52
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Lisyanskaya A, Crispens M, et al. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecol Oncol 2009;114:288-92
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008;105:8713-17
   PubMed Web of Science ®Google Scholar
• Konecny GE, Kolarova T, O’Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 2013;12:632-42
   PubMed Web of Science ®Google Scholar
• Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129:22-7
   PubMed Web of Science ®Google Scholar
• Eritja N, Domingo M, Dosil MA, et al. Combinatorial therapy using dovitinib and ICI182.780 (Fulvestrant) blocks tumoral activity of endometrial cancer cells. Mol Cancer Ther 2014;13:776-87
   PubMed Web of Science ®Google Scholar
• Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014;25:32-40
   PubMed Web of Science ®Google Scholar